Abstract: Techniques, systems and methods for designing, implementing, and operating model predictive controllers that can deliver perfect tracking of set points and that can reject the effect of disturbances when steady-state operation is reached are disclosed. High performance is achieved through the incorporation of set-point tracking costs, integral costs, and velocity costs, as well as the adoption of incremental model systems for prediction purposes. Embodiments can deliver offset-free performance for tracking set points with constant final values, set points of a ramp type, and set points of a parabolic form, while rejecting disturbances that have a constant final value. The approach reduces the complexity of model predictive control design, delivers improved performance, and requires modest computational power.

Abstract: Techniques, systems and methods for designing, implementing, and operating model predictive controllers that can deliver perfect tracking of set points and that can reject the effect of disturbances when steady-state operation is reached are disclosed. High performance is achieved through the incorporation of set-point tracking costs, integral costs, and velocity costs, as well as the adoption of incremental model systems for prediction purposes. Embodiments can deliver offset-free performance for tracking set points with constant final values, set points of a ramp type, and set points of a parabolic form, while rejecting disturbances that have a constant final value. The approach reduces the complexity of model predictive control design, delivers improved performance, and requires modest computational power.

Abstract: Both liquid and dry form Morinda citrifolia enhanced animal food products are provides. Both contain pasteurized fruit puree and other M. citifolia plant products.

Abstract: Compounds having quinone and quinone analogs useful for pharmaceutical preparations have now been found which inhibit cysteine proteases, in particular, caspases and 3C-cysteine proteases. The cysteine protease inhibitors of the present invention can be identified by their mode of action in disrupting the ability of cysteine proteases and, in particular, caspases to cleave a peptide chain. These compounds are useful in inhibiting cysteine protease or cysteine protease-like proteins and for treating infections diseases or physiopathological diseases or disorders attributed to the presence of excessive or insufficient levels of cysteine proteases.

Abstract: A method for identifying molecules and designing novel pharmaceuticals is disclosed. The disclosed method of novel pharmaceutical design identifies a novel chemical group that triggers a mechanism of action for an identified reaction, thereby avoiding the various structural complexities associated with the application of the structure-based drug design. Additionally, examples of potential therapeutics identified by the mechanism based drug design method are provided.

Abstract: Libraries for use in a multithreaded computer environment which must be thread-safe and cannot be recoded are identified. Such libraries, after identification, are repackaged. Export routines for such libraries will thereby acquire a front end which effects several steps. First a write-exclusive lock for a particular called function of one of the libraries is generically acquired. A call is then made to the underlying function whose name has been remapped. Upon return from the real routine, the write-exclusive lock is unlocked and a return to the user is executed. The system and method ensure correct functioning and integrity of the identified library functions accessible by multiple threads, as well as providing for creation of multithread-safe shared libraries without necessitating extensive library source modifications.